Page 65 - Test PDF v5

« Back to Contents MISCELLANEOUS

LiFE re

Literature for ENYGO

Immunotherapy in gynaecological cancers

Editor Zoltan Novak

Descriptive summary The study investigated if imiquimod applied at the vaccine site
could improve CD8+ T-cell reactivity, clinical efficacy, and safety of
In this update, three recent human gynaecologic cancer/precancer HPV16-synthetic long-peptide vaccination. Vaccine-induced clinical
immunotherapy trials are reported. In a phase I/II trial, 14 high-risk responses were observed in 18 of 34 (53 %) patients at 3 months, 8
disease-free ovarian and breast cancer patients were vaccinated of whom displayed a complete histological response. Viral clearance
with MUC1, ErbB2, and carcinoembryonic antigen peptides and occurred in all but one of the patients with complete histological
montanide adjuvant after completion of standard therapies. 8 out clearance, but imiquimod did not improve the outcomes of vacci-
of 14 patients showed specific CD8+ T cells to at least one antigen. nation [3]. A paper reviewed the role of microsatellite instability
Peptide vaccination proved to be safe and well-tolerated. Vaccina- (MSI) testing in predicting the clinical benefit of immune checkpoint
tion generated a long-lasting immune and some clinical response, blockade with anti-programmed death 1 inhibitors. If initial results
having registered no deceased patients with a minimum follow-up of are validated, MSI testing could have an expanded role as a tool in
8 years. [1] the armamentarium of precision medicine [4]. Also see the report on
“Pathology in endometrial cancer (prognostic factors, EIN, EIC)” by
In a randomised, double-blind, placebo-controlled phase IIb study, S. Scasso.
efficacy, safety, and immunogenicity of VGX-3100 synthetic plasmid
vaccine targeting HPV-16 and HPV-18 E6 and E7 proteins were
assessed in patients with CIN2/3. In the modified intention-to-treat
analysis 55 (48·2 %) of 114 VGX-3100 recipients and 12 (30·0 %) of
40 placebo recipients had histopathological regression, which was
statistically significant (p=0·034) [2]. Another multicentre open-label,
randomised controlled trial was conducted in patients with HPV16+
high-grade VIN/VaIN.

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract
Antonilli M et al. Int J Oncol. http://www.spandidos-publications.
1 Triple peptide vaccination as consolidation treatment in women affected by com/10.3892/ijo.2016.3386
ovarian and breast cancer: Clinical and immunological data of a phase I/II Trimble CL et al. Lancet.
clinical trial. https://ncbi.nlm.nih.gov/pub-
van Poelgeest MI et al. Clin Cancer Res. med/26386540
2 Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic
DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins Dudley JC et al. Clin Cancer Res. https://ncbi.nlm.nih.gov/pub-
for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, med/26813357
placebo-controlled phase 2b trial. https://ncbi.nlm.nih.gov/pub-
med/26880610
3 Vaccination against oncoproteins of HPV16 for non-invasive vulvar/vaginal
lesions: lesion clearance is related to the strength of the T-cell response.

4 Microsatellite Instability as a Biomarker for PD-1 Blockade.

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 65